Discover
TSHA
Taysha Gene Therapies, Inc.
5.04
2 x 3.71
2 x 6.40
bid
ask
+
0.03
0.50%
10:27 AM
timesize
| Ytd | -8.27% | |
| 1y | 78.27% |
5.00
day range
5.12
2.71
52 week range
7.30
| Open | 5.07 | Prev Close | 5.02 | Low | 5.00 | High | 5.12 | Mkt Cap | 1.64B |
| Vol | 149.10K | Avg Vol | 3.27M | EPS | -0.41 | P/E | N/A | Forward P/E | -10.85 |
| Beta | 1.19 | Short Ratio | 18.16 | Inst. Own | 94.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 5.81 | 200-d Avg | 5.47 | 1yr Est | 13.00 |
| Income Statement | |||
| Operating Expenses | 47.35M | ||
| Research and Development Expense | 38.64M | ||
| Selling, General and Administrative Expense | 12.15M | ||
| Operating Income | -47.35M | ||
| Interest Expense | 6.00K | ||
| Net Income | -46.64M | ||
| Net Income Common Stock | -46.64M | ||
| Net Income Common Stock (USD) | -46.64M | ||
| Consolidated Income | -46.64M | ||
| Earnings per Basic Share | -0.13 | ||
| Earnings per Basic Share (USD) | -0.13 | ||
| Earnings per Diluted Share | -0.13 | ||
| Earning Before Interest & Taxes (EBIT) | -46.63M | ||
| Earning Before Interest & Taxes (USD) | -46.63M | ||
| Weighted Average Shares | 369.04M | ||
| Weighted Average Shares Diluted | 369.04M | ||
| Balance Sheet | |||
| Cash and Equivalents | 455.57M | ||
| Cash and Equivalents (USD) | 455.57M | ||
| Current Assets | 461.43M | ||
| Property, Plant & Equipment Net | 8.73M | ||
| Total Assets | 470.43M | ||
| Total Debt | 55.55M | ||
| Current Liabilities | 25.98M | ||
| Debt Non-Current | 55.55M | ||
| Total Liabilities | 83.17M | ||
| Accumulated Retained Earnings (Deficit) | -800.35M | ||
| Accumulated Other Comprehensive Income | 769.00K | ||
| Shareholders Equity | 387.27M | ||
| Shareholders Equity (USD) | 387.27M | ||
| Assets Non-Current | 9.00M | ||
| Total Debt (USD) | 55.55M | ||
| Liabilities Non-Current | 57.19M | ||
| Trade and Non-Trade Payables | 9.16M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 562.00K | ||
| Net Cash Flow from Financing | 216.66M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 176.23M | ||
| Capital Expenditure | 1000 | ||
| Issuance (Purchase) of Equity Shares | 216.58M | ||
| Net Cash Flow from Investing | 1000 | ||
| Net Cash Flow from Operations | -40.42M | ||
| Share Based Compensation | 5.81M | ||